August 2025
1. MILHEM MM, Zakharia Y, Davar D, Buchbinder EI, et al
   Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study.
   Cancer. 2025;131:e70022.
   

   >> Share

   
   July 2025
2. MENZIES AM, Salman P, Frontera OA, Pook D, et al
   Administration of nivolumab plus ipilimumab: Infusion of the fixed-ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800).
   Cancer. 2025;131:e35962.
   

   >> Share

   
   
3. KIM Y, Doma V, Cakir U, Kuras M, et al
   Mitochondrial proteome landscape unveils key insights into melanoma severity and treatment strategies.
   Cancer. 2025;131:e35897.
   

   >> Share

   
   June 2025
4. NIERENGARTEN MB
   New standard of care for patients with asymptomatic brain metastases from melanoma.
   Cancer. 2025;131:e35885.
   

   >> Share

   
   May 2025
5. CHEN MF, Postow MA
   Top advances of the year: Neoadjuvant immunotherapy in melanoma.
   Cancer. 2025;131:e35877.
   

   >> Share

   
   
6. NIERENGARTEN MB
   Two-fold increased risk of melanoma in childhood cancer survivors.
   Cancer. 2025;131:e35828.
   

   >> Share

   
   January 2025
7. PASSMAN JE, Kallan MJ, Roberson JL, Ginzberg SP, et al
   Contemporary trends in utilization of metastasectomy in the era of targeted and immunotherapies.
   Cancer. 2025;131:e35664.
   

   >> Share

   
   December 2024
8. DANIELSEN JT, Zachariae R, Schmidt H, Kallehauge JF, et al
   Cognitive impairment in patients with melanoma before adjuvant immune checkpoint inhibitor therapy and associations with brain gray matter, catechol-O-methyltransferase genotype, and psychological factors.
   Cancer. 2024 Dec 11. doi: 10.1002/cncr.35683.
   

   >> Share

   
   
9. LE BRUN IC, Dalle S, Mortier L, Dereure O, et al
   Methods of nivolumab administration in advanced melanoma: A comparison of patients' clinical outcomes treated with flat dose or weight-adjusted dose, a multicenter observational study.
   Cancer. 2024 Dec 8. doi: 10.1002/cncr.35679.
   

   >> Share

   
   November 2024
10. DEPALO DK, Dugan MM, Naqvi SMH, Ollila DW, et al
    A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first-line treatment for patients with melanoma in-transit metastases.
    Cancer. 2024 Nov 10. doi: 10.1002/cncr.35636.
    

    >> Share

    
    September 2024
11. LAO CD, Moon J, Ma VT, Fruehauf JP, et al
    Southwest Oncology Group S0826: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma.
    Cancer. 2024 Sep 29. doi: 10.1002/cncr.35587.
    

    >> Share

    
    July 2024
12. ROZEMAN EA, Luke JJ
    The emergence of neoadjuvant immune-over BRAF therapy in melanoma.
    Cancer. 2024 Jul 22. doi: 10.1002/cncr.35490.
    

    >> Share

    
    June 2024
13. YABROFF KR, Mittu K, Halpern MT
    Cost-of-care discussions for individuals with advanced non-small cell lung cancer and melanoma: Findings from a large, population-based pilot study.
    Cancer. 2024 Jun 13. doi: 10.1002/cncr.35380.
    

    >> Share

    
    
14. CZARNECKA AM, Ostaszewski K, Blonski PJ, Szumera-Cieckiewicz A, et al
    Long-term efficacy of neoadjuvant-adjuvant targeted therapy in borderline resectable stage IIIB-D and IV melanoma.
    Cancer. 2024 Jun 6. doi: 10.1002/cncr.35425.
    

    >> Share

    
    April 2024
15. KHATTAK MA, Luke JJ
    Top advances of the year: Melanoma.
    Cancer. 2024 Apr 29. doi: 10.1002/cncr.35354.
    

    >> Share

    
    March 2024
16. ROSENBERG SM, McCue S, He J, Lafky JM, et al
    Alliance A151945: Accrual and characteristics of adolescent and young adult patients in Alliance trials from 2000 to 2017.
    Cancer. 2024;130:750-769.
    

    >> Share

    
    January 2024
17. VAN NOT OJ, van den Eertwegh AJM, Haanen JB, van Rijn RS, et al
    BRAF/MEK inhibitor rechallenge in advanced melanoma patients.
    Cancer. 2024 Jan 10. doi: 10.1002/cncr.35178.
    

    >> Share

    
    October 2023
18. NIERENGARTEN MB
    First person profile: Jedd Wolchok, MD: Advances in treating metastatic melanoma can, in part, be charted by the career of Dr Wolchok, who was on the front lines of investigating immunotherapy science and developed the first immunologic agents to trea
    Cancer. 2023;129:3190-3191.
    

    >> Share

    
    September 2023
19. EROGLU Z, Chen YA, Smalley I, Li J, et al
    Combined BRAF, MEK, and heat-shock protein 90 (HSP90) inhibition in advanced BRAF V600-mutant melanoma.
    Cancer. 2023 Sep 30. doi: 10.1002/cncr.35029.
    

    >> Share

    
    July 2023
20. MOORADIAN MJ, Sullivan RJ
    The case for adjuvant BRAF-targeted therapy versus adjuvant anti-PD-1 therapy for patients with resected, high-risk melanoma.
    Cancer. 2023;129:2117-2121.
    

    >> Share

    
    
21. NIERENGARTEN MB
    Neoadjuvant immunotherapy improves outlook in high-risk melanoma.
    Cancer. 2023;129:1952.
    

    >> Share

    
    June 2023
22. DEMKOWICZ P, Pointdujour-Lim R, Miguez S, Lee Y, et al
    Determinants of overall survival in patients with metastatic uveal melanoma.
    Cancer. 2023 Jun 29. doi: 10.1002/cncr.34927.
    

    >> Share

    
    
23. MOORADIAN MJ, Cleary JM, Giobbie-Hurder A, Darville LNF, et al
    Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors.
    Cancer. 2023;129:1904-1918.
    

    >> Share

    
    May 2023
24. PATUZZO R, Mattavelli I, Gallino G, Galeone C, et al
    The prognostic role of mitotic rate in cutaneous malignant melanoma: Evidence from a multicenter study on behalf of the Italian Melanoma Intergroup.
    Cancer. 2023 May 10. doi: 10.1002/cncr.34824.
    

    >> Share

    
    
25. GERSHENWALD JE
    Mitotic rate in primary cutaneous melanoma: Cell division matters.
    Cancer. 2023 May 10. doi: 10.1002/cncr.34825.
    

    >> Share

    
    April 2023
26. GALUS L, Michalak M, Lorenz M, Stoinska-Swiniarek R, et al
    Vitamin D supplementation increases objective response rate and prolongs progression-free time in patients with advanced melanoma undergoing anti-PD1 therapy.
    Cancer. 2023 Apr 24. doi: 10.1002/cncr.34718.
    

    >> Share

    
    March 2023
27. LEV-ARI S, Serzan M, Wu T, Ip A, et al
    The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real-world, multicenter, retrospective study.
    Cancer. 2023 Mar 23. doi: 10.1002/cncr.34742.
    

    >> Share

    
    
28. EROGLU Z, Krinshpun S, Kalashnikova E, Sudhaman S, et al
    Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients.
    Cancer. 2023 Mar 4. doi: 10.1002/cncr.34716.
    

    >> Share

    
    January 2023
29. KLEIN O, Kee D, Nagrial A, Markman B, et al
    Is there a role for combined anti-PD-1/CTLA-4 checkpoint blockade in the management of advanced biliary tract cancers?
    Cancer. 2023 Jan 24. doi: 10.1002/cncr.34660.
    

    >> Share

    
    
30. SAHAI V, Zalupski MM
    Reply to "Is there a role for combined anti-PD-1/CTLA-4 checkpoint blockade in the management of advanced biliary tract cancers?".
    Cancer. 2023 Jan 24. doi: 10.1002/cncr.34659.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share